Watch the webinar recording
Lars Rydén, Christina Jarnert and Oliver Schnell
This course focuses on diagnostic and therapeutic considerations for patients with acute coronary syndromes and with previously unknown glucose perturbations.
It will cover aspects of patient management from the acute hospitalization to secondary preventive measures during long-term follow up.
The ESC webinars are designed to help you improve your daily practice!
The format includes a case based presentation, online assesssment and live discussions with the two key opinion leaders who will deliver useful tips for your daily clinical practice.
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC)
|
Your questions |
Comments from Professor Rydén |
|---|---|
| Could you comment on strength of different statins in both LDL-lowering and HLD-increase | Statins do usually not influence HDL cholesterol. One that may increase it somewhat is rosuvastatin. Simvastatin 40 mg has by experience a lower effect on LDL than e.g. rosuvastatin 20 mg. The use of high dosages of simva may decrease LDL but side effects start to be more common and it nay be better toi switch to a (lower) dose of a more effective statin. |
| Could you please repeat why is not measurable LDL-C after MI? | It can be measured at admission but the nearest time thereafter it is influenced of the acute illness and is therefore better measured after a month or so. |
| Do we have any trials, concerning rozuvastatin vs atorvastatin effect on events? | No there are no head-to-head comparisons. |
| At our institution, atorvastatin 80mg is now recommended for all post-MI patients. Is the evidence regarding this strong enough? | No, all statins are useful and it is rather the impact of LDL that is important. Thus if you can reach (in a diabetes pat) a LDL of recommended value (target) the type of statin probably is of less importance. |
| What do You thing about role of CETP inhibitors. Proveded studies didn´t led to expected results | Just now the results are disappointing and they should not be used. |
| How often do you see statin-induced hepatitis? What treatment do you provide in this case? | Very, very seldom of any great importance and my experience of serious such conditions is therefore not good enough to give a recommendation. Statins should be discharged of course as soon as possible and this is in mild cases enough. |
Our mission: To reduce the burden of cardiovascular disease.